Literature DB >> 2573481

Is neuroleptic dysphoria a healthy response?

P J Weiden1, J J Mann, L Dixon, G Haas, N DeChillo, A J Frances.   

Abstract

We examined the relationship between neuroleptic-induced extrapyramidal effects, subjective neuroleptic dysphoria, and clinical outcome in acutely psychotic inpatients. Thirteen of 50 consecutively admitted patients experienced severe neuroleptic dysphoria. Dysphoric patients were less likely to comply with neuroleptic, but nine did complete neuroleptic trials. The compliant dysphoric inpatients received significantly lower neuroleptic doses compared with nondysphoric patients, and yet had equivalent overall improvement of psychotic symptoms and less severe extrapyramidal effects. Despite having fewer physical signs of akinesia, dysphoric patients were significantly more distressed from akinesia than nondysphoric. We conclude that while some neuroleptic dysphoric patients become noncompliant, others benefit from dysphoria by negotiating for lower, less toxic, and yet effective neuroleptic dosages.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573481     DOI: 10.1016/0010-440x(89)90085-0

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  4 in total

1.  Psychopathology and quality of life in schizophrenia.

Authors:  S Packer; J Husted; S Cohen; G Tomlinson
Journal:  J Psychiatry Neurosci       Date:  1997-07       Impact factor: 6.186

Review 2.  Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.

Authors:  Hanjing Emily Wu; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2015-06

Review 3.  Neuroleptic dysphoria: towards a new synthesis.

Authors:  L Voruganti; A G Awad
Journal:  Psychopharmacology (Berl)       Date:  2003-11-27       Impact factor: 4.530

Review 4.  The impact of subjective well-being under neuroleptic treatment on compliance and remission.

Authors:  Walter de Millas; Martin Lambert; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.